Calculated based on number of publications stored in Pure and citations from Scopus
20082023

Research activity per year

Personal profile

Public Profile

Dr Eadie is an award-winning biomedical researcher and a Cancer Council South Australia Beat Cancer Project Fellow, awarded to the top two mid-career cancer researchers in South Australia (2023-current). She is an Australian Institute of Policy and Science Young Tall Poppy (2023), previous Fulbright scholar and a TEDx speaker.

Dr Eadie has been awarded >$4 million in fellowship/grant funding in the last five years, >$2 million as CIA from funding bodies including NHMRC, MRFF, Leukaemia Foundation, Cancer Council. Dr Eadie has built an international reputation as an emerging leader in the use of patient genomics to inform therapy outcomes for Acute Lymphoblastic Leukaemia (ALL) patients, evidenced by an American Society of Hematology Achievement Award (2020) and an International Thermo Fisher Cancer Research Grant (2022).

ALL is one of the biggest causes of non-traumatic death in children and relapsed T-cell ALL (T-ALL) is an extremely high risk disease. More effective, less toxic treatments are urgently needed for when a patient fails their front-line chemotherapy. Dr Eadie is SAHMRI's T-ALL research leader and her team creates humanised mouse avatars from individual patient’s leukaemic cells to use in pre-clinical drug trials. Combined with genomic sequencing to identify a patient’s leukaemia-causing mutations, these models allow Dr Eadie to discover more effective therapeutic options targeted to each individual patient’s leukaemia.

Dr Eadie's long-term research goal is to identify new and re-purposed drugs which effectively treat the different genetic lesions associated with T-ALL. Her team's findings will ultimately provide clinicians with an arsenal of alternative treatment options and hope for patients who have relapsed.

Public Profile

Research Focus 

T-cell acute lymphoblastic leukaemia (T-ALL) is a rare but high-risk disease affecting both children and adults. T-ALL patients are universally treated with several years of toxic, high-dose, non-selective chemotherapy which is associated with significant rates of treatment related mortality. Recent improvements to chemotherapy regimens have led to better outcomes for de novo paediatric T-ALL patients. However, the principal clinical issue in ALL is treatment resistance where up to 25% of paediatric/adolescent patients relapse and experience poor overall survival. The outlook is worse for adult T-ALL patients: 40% demonstrate primary chemotherapy resistance and most older adults will die of their disease. There is a major unmet need to identify innovative and targeted therapies for use in frontline treatment regimens to prevent resistance and relapse.

Dr Eadie's research program utilises genomic sequencing to identify novel and targetable T-ALL alterations to accelerate a transition towards precision medicine to improve clinical outcomes. Dr Eadie's Research Group is part of the SAHMRI ALL Genomics and Functional Genomics/Biology Laboratory led by Prof Deborah White (leader, SAHMRI Precision Cancer Medicine Theme). Together, with the ALL bioinformatic team, Dr Eadie has curated the largest genomic sequencing database of T-ALL patients in Australia. Dr Eadie has identified novel leukaemia-causing alterations as well as new treatment options for several high-risk ALL subtypes. 

Education/Academic qualification

PhD, Doctor of Philosophy, University of Adelaide

30 Mar 200927 Mar 2013

Award Date: 31 Jul 2013

Bachelor's Degree (Honours), Honours Degree of Bachelor of Science, University of Adelaide

17 Jan 20062 Dec 2006

Award Date: 20 Dec 2006

Bachelor's Degree, BSc (Biomed), University of Adelaide

22 Jan 20032 Dec 2005

Award Date: 22 Dec 2005

External positions

Affiliate Senior Lecturer Discipline of Medicine, University of Adelaide

Apr 2020 → …

Post Doctoral Research Associate, St. Jude Children Research Hospital

14 Aug 201615 Aug 2017

Affiliate Lecturer Discipline of Medicine, University of Adelaide

Apr 2014Apr 2020

Keywords

  • acute lymphoblastic leukaemia
  • mouse models
  • next generation sequencing
  • drug resistance
  • leukaemia

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or